New pricing directive proposals fail to address real issue, says EFPIA
This article was originally published in Scrip
Executive Summary
Proposals to reform the European directive on pharmaceutical pricing processes are a step in the right direction, but there needs to be a wider debate on international price referencing systems that are costing industry billions of Euros worldwide and preventing differential pricing, EFPIA's director general, Richard Bergstrom, told Scrip.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.